Albania recently approved clinical guidelines for gender-affirming hormone therapy, marking a step forward for transgender healthcare in the country. However, the announcement ignited online controversy surrounding potential state subsidies for this treatment. Despite the public debate, official documentation clarifies that the government will *not* be providing financial reimbursement for the medications involved. This means transgender individuals will be responsible for the full cost of hormone therapy. While access to the therapy itself is now sanctioned under medical guidelines, affordability remains a significant barrier. The approval is still considered a positive development by advocates, but the lack of financial support raises concerns about equitable access to care. The situation highlights a common challenge for transgender healthcare globally – legal access doesn’t always equate to practical accessibility.